Maze Therapeutics (NASDAQ:MAZE) Stock Keeps “Buy” Rating at HC Wainwright

Maze Therapeutics (NASDAQ:MAZE)‘s stock had its “buy” rating reiterated by HC Wainwright in a research note issued on Thursday, Benzinga reports. They currently have a $110.00 target price on the stock. HC Wainwright’s price target points to a potential upside of 304.71% from the company’s previous close.

Several other equities research analysts have also weighed in on MAZE. Wedbush reiterated an “outperform” rating and set a $48.00 price objective on shares of Maze Therapeutics in a research note on Wednesday, September 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Maze Therapeutics in a report on Monday, September 21st. TD Cowen upgraded Maze Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th. BTIG Research restated a “buy” rating and set a $46.00 price objective on shares of Maze Therapeutics in a research report on Tuesday, September 22nd. Finally, Wall Street Zen downgraded Maze Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Three analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Maze Therapeutics has a consensus rating of “Buy” and an average target price of $63.40.

Maze Therapeutics Stock Performance

MAZE stock traded up $0.16 during trading on Thursday, hitting $27.18. 518,008 shares of the company’s stock traded hands, compared to its average volume of 666,225. The stock has a market capitalization of $1.51 billion, a price-to-earnings ratio of -10.79 and a beta of 2.17. Maze Therapeutics has a 52 week low of $21.95 and a 52 week high of $53.65. The stock has a fifty day moving average price of $27.04 and a two-hundred day moving average price of $28.57. The company has a quick ratio of 18.31, a current ratio of 18.31 and a debt-to-equity ratio of 0.09.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.76). As a group, equities analysts anticipate that Maze Therapeutics will post -2.72 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CMO Harold Bernstein sold 16,142 shares of the business’s stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $27.61, for a total transaction of $445,680.62. Following the completion of the transaction, the chief marketing officer directly owned 16,142 shares in the company, valued at approximately $445,680.62. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jason V. Coloma sold 34,501 shares of the stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $26.29, for a total value of $907,031.29. Following the completion of the transaction, the chief executive officer directly owned 18,151 shares of the company’s stock, valued at $477,189.79. This trade represents a 65.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 134,849 shares of company stock worth $3,582,240. Insiders own 5.30% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of Maze Therapeutics in the second quarter worth $48,000. Royal Bank of Canada raised its stake in shares of Maze Therapeutics by 214.1% during the first quarter. Royal Bank of Canada now owns 2,029 shares of the company’s stock valued at $61,000 after purchasing an additional 1,383 shares in the last quarter. Quantbot Technologies LP bought a new stake in shares of Maze Therapeutics during the second quarter valued at about $80,000. Caitong International Asset Management Co. Ltd acquired a new stake in Maze Therapeutics in the fourth quarter worth about $145,000. Finally, IFP Advisors Inc acquired a new stake in Maze Therapeutics in the fourth quarter worth about $146,000.

Maze Therapeutics Company Profile

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically driven diseases. The company combines human genetics, functional genomics and drug discovery technologies through its Maze Compass platform to identify disease mechanisms and develop therapies designed to address the underlying causes of disease.

Maze’s lead program, MZE001, is an oral small-molecule inhibitor of glycogen synthase being developed for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles and other tissues.